| Celldex loses half its market value after failure of brain cancer vaccine The trial failure is particularly heartbreaking considering there have been few developments of drugs to treat the 23,000 people a year in the U.S. who are diagnosed with the disease. InVivo shares surge after third patient improves with spinal scaffold InVivo’s shares were up 23 percent as of 11:50 a.m. Monday after the news Monday to give the stock a value of $8.90 for the first time since December. NIH to fund trial of pill to treat lupus owned by Norwood's Corbus Pharma The Norwood biotech said this morning that the National Institutes of Health will foot the bill for a 100-patient Phase 2 trial of its drug, Resunab, in patients with the autoimmune disease. Could Biogen and Shire merge? One blogger lays out the case The blog, written by Ed Wijaranakula of NMS Investment Research, argues that aside from being a tax-inversion deal for Biogen, the merger would fill both company’s expressed wishes to grow revenues quickly. | 
